drugset / Trial / NCT00786305
Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
RandomizedParallel-groupOpen-labelTreatment
Summary
Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated patients.
Timeline
- Start
- 2004-10
- Primary completion
- 2008-09
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amikacin | Small molecule | 15 mg/kg | Other |
| Comparator | Amikacin | Small molecule | 25 mg/kg | Other |
| Comparator | Ceftazidime | Small molecule | 15 mg/kg | Other |
| Comparator | Ceftazidime | Small molecule | 90 mg/kg | Other |